Search terms included combinations of “GLP-1 receptor agonists,” “heart failure,” “preserved ejection fraction,” “reduced ejection fraction,” “HFpEF,” “HFrEF,” “tirzepatide,” “semaglutide,” “liraglutide,” “cardiometabolic,” and “functional capacity.” Priority was given to randomized controlled trials (RCTs), meta-analyses, and mechanistic studies, particularly those reporting cardiovascular outcomes or HF-specific endpoints. This evidence concerns the gene GLP1R and hydrops fetalis.